Targapremir-210 TGP-210|cas:1049722-30-6|西域试剂

Targapremir-210 TGP-210,98.00%

产品编号：Bellancom-15861| CAS NO：1049722-30-6| 分子式：C₃₂H₃₆N₁₀O₂| 分子量：592.69

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15861	￥4500.00	杭州北京（现货）
Bellancom-15861	￥7500.00	杭州北京（现货）
Bellancom-15861	￥13500.00	杭州北京（现货）
Bellancom-15861	￥22500.00	杭州北京（现货）
Bellancom-15861	￥33500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Targapremir-210 TGP-210

产品介绍

Targapremir-210 (TGP-210) 是一种有效的、选择性的 miR-210 (miRNA-210, microRNA-210) 抑制剂。 Targapremir-210 以高亲和力抑制 pre-miR-210 的加工 (K_d~200 nM)。

生物活性

Targapremir-210 (TGP-210) is a potent and selective miR-210 (miRNA-210, microRNA-210) inhibitor. Targapremir-210 inhibits pre-miR-210 processing with high binding affinity (K_d~200 nM).

体外研究

Targapremir-210 decreases mature miR-210 levels in MDA-MB-231 cells cultured under hypoxic conditions, with an IC₅₀ of ∼200 nM.
Targapremir-210 (200 nM) induces MDA-MB-231 cells apoptosis is selective for the hypoxic environment. Targapremir-210 induces cells apoptosis under hypoxic conditions and does not induce apoptosis in MDA-MB-231 cells cultured in normoxia.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Targapremir-210 (100 μL of 200 nM; single i.p. injection) impedes MDA-MB-231 triple negative breast cancer (TNBC) cells proliferation in vivo. Targapremir-210 is able to reach the tumor and sustain for the entire 21-day period, and decreases tumor burden in a TNBC mouse model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice were subcutaneously transplanted cell suspension into breast fat pads.
Dosage:	100 μL of 200 nM
Administration:	Single i.p. injection 24 h post-transplantation
Result:	Decreased tumor growth as assessed by luciferase signal intensity and mass of the resected tumor.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice were subcutaneously transplanted cell suspension into breast fat pads.
Dosage:	100 μL of 200 nM
Administration:	Single i.p. injection 24 h post-transplantation
Result:	Decreased tumor growth as assessed by luciferase signal intensity and mass of the resected tumor.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (421.81 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6872 mL	8.4361 mL	16.8722 mL
5 mM	0.3374 mL	1.6872 mL	3.3744 mL
10 mM	0.1687 mL	0.8436 mL	1.6872 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.51 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.51 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明